82 related articles for article (PubMed ID: 8370633)
1. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients.
Luke DR; McCreedy BJ; Sarnoski TP; Bookout JB; Johnston AM; Lell JE; Wiggan EB; Bell N; Limjuco RA; Guthrie KI
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):343-50. PubMed ID: 8370633
[TBL] [Abstract][Full Text] [Related]
2. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
3. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
5. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
7. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
8. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
9. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
[TBL] [Abstract][Full Text] [Related]
10. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
11. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
14. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
Opravil M; Hill AM; DeMasi R; Dawson D
Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.
Lissoni P; Ardizzoia A; Perego MS; Grassi MG; Arosio M; D'Amico P; Cazzaniga M; Crispino S; Tancini G; Barni S
J Biol Regul Homeost Agents; 1993; 7(2):73-5. PubMed ID: 8266818
[TBL] [Abstract][Full Text] [Related]
16. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
Dezube BJ; Pardee AB; Chapman B; Beckett LA; Korvick JA; Novick WJ; Chiurco J; Kasdan P; Ahlers CM; Ecto LT
J Acquir Immune Defic Syndr (1988); 1993 Jul; 6(7):787-94. PubMed ID: 8099612
[TBL] [Abstract][Full Text] [Related]
17. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Dezube BJ; Lederman MM; Spritzler JG; Chapman B; Korvick JA; Flexner C; Dando S; Mattiacci MR; Ahlers CM; Zhang L
J Infect Dis; 1995 Jun; 171(6):1628-32. PubMed ID: 7769305
[TBL] [Abstract][Full Text] [Related]
18. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
Ogino MT; Dankner WM; Spector SA
J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline for the treatment of HIV infection and its complications.
Dezube BJ; Lederman MM
J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S139-42. PubMed ID: 8699854
[TBL] [Abstract][Full Text] [Related]
20. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
Int J Immunopharmacol; 1990; 12(7):737-41. PubMed ID: 2127261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
